Ablynx - Publication in accordance with §14 of the Belgian law of 2/5/2007 regarding the publication of major shareholdings (the "transparancy" law)

 

Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from FMR LLC on 31 October and 1 November 2017.

In a first notification (dated 31 October 2017), FMR LLC (taking into account the holdings of its subsidiary undertakings) notified Ablynx that they hold 7,024,629 voting securities of Ablynx and equivalent financial instruments on 25 October 2017, representing 11.41% of the 61,576,144 outstanding voting rights of Ablynx at that time.

 

In a second notification (dated 1 November 2017), FMR LLC (taking into account the holdings of its subsidiary undertakings) notified Ablynx that they hold 7,017,029 voting securities of Ablynx and equivalent financial instruments on 26 October 2017, representing 11.40% of the 61,576,144 outstanding voting rights of Ablynx at that time.

 

The second notification contains the following information:

  • Reason for the notification: acquisition or disposal of voting securities or voting rights
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement: FMR LLC, The Corporation Trust Center, 1209 Orange Street, Wilmington, Delaware 19801, USA
  • Transaction date: 26 October 2017
  • Threshold that is crossed: 10%
  • Denominator: 61,576,144 (on 26/10/2017)
  • Details of the notification:

Name of select subsidiaries of

FMR LLC

% of voting rights

% of voting rights held through financial instruments*

Total of both

FMR LLC

Fidelity Management & Research Company

FMR Co., Inc.

7.40%

1.37%

8.77%

FMR LLC

FIAM Holdings Corp.

Fidelity Institutional Asset Management Trust Company

1.41%

 

1.41%

FMR LLC

FIAM Holdings Corp.

FIAM LLC

1.22%

 

1.22%

TOTAL

10.03%

1.37%

11.40%

* Type of financial instrument: "Right of Recall

 

  • Chain of controlled undertakings through which the holding is effectively being held: The holdings attributable to FMR LLC arise from holdings of various undertakings for collective investment that are managed by FMR Co., Inc., Fidelity Institutional Asset Management Trust Company and FIAM LLC, each of which are entities that are subsidiaries of, and controlled by, FMR LLC. These undertakings for collective investment have granted FMR LLC discretionary power to vote the securities in accordance with the FMR LLC board proxy voting policy. FMR LLC is not a controlled undertaking.

 

More information is provided in the transparency notification. Full versions of both transparency notifications are available on Ablynx website, under the section Investors.

 

The Articles of the Association of Ablynx NV provide for shareholders notification threshold of 3%, 5% or a multiple of 5% of the total number of existing voting rights.

Note

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?